Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant

NCT02786485 is registered in ClinicalTrials.gov with Bellicum Pharmaceuticals as lead sponsor.

NCT NCT02786485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02786485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Lead sponsor
Bellicum Pharmaceuticals
Phase
Phase 1
Overall status
Withdrawn
Start date
May 31, 2016
Completion date
December 31, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphomas, multiple myeloma, myelodysplastic syndromes, other high-risk hematological malignancies